The statistically significant responder analysis results for Mytesi® (crofelemer) in the OnTarget study's prespecified subgroup of patients with breast cancer were the subject of a December 2024 poste ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback